Arcus Biosciences, Inc. (RCUS)
RCUS price $19.10 -4.65 -19.58%
- Ticker
- RCUS
- Price
- $19.10
- Change
- -4.65 -19.58%
- Market cap
- $2.40B
- P/E
- -4.88
- Forward P/E
- 16.71
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 47
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1…